(Arg14,Lys15)Nociceptin

From WikiMD's Medical Encyclopedia

Revision as of 20:59, 1 December 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

(Arg14,Lys15)Nociceptin

(Arg14,Lys15)Nociceptin is a synthetic peptide analog of the naturally occurring neuropeptide nociceptin, also known as orphanin FQ. This modified peptide is characterized by the substitution of arginine (Arg) at position 14 and lysine (Lys) at position 15 in the nociceptin sequence. These modifications are designed to alter the peptide's interaction with the nociceptin receptor (NOP receptor), which is a member of the opioid receptor family.

Structure and Synthesis[edit]

(Arg14,Lys15)Nociceptin is synthesized through solid-phase peptide synthesis, a method commonly used to produce peptides with specific amino acid sequences. The peptide sequence of nociceptin is modified at positions 14 and 15 to include arginine and lysine, respectively, which are basic amino acids that can influence the peptide's charge and receptor binding properties.

Pharmacological Properties[edit]

The pharmacological properties of (Arg14,Lys15)Nociceptin are of significant interest due to its potential effects on the NOP receptor. This receptor is involved in modulating pain, mood, and various physiological processes. By altering the peptide sequence, researchers aim to study changes in receptor affinity, efficacy, and selectivity.

Receptor Binding[edit]

(Arg14,Lys15)Nociceptin exhibits altered binding affinity to the NOP receptor compared to native nociceptin. The introduction of positively charged residues at positions 14 and 15 may enhance or reduce binding affinity, depending on the receptor's binding pocket characteristics.

Functional Activity[edit]

The functional activity of (Arg14,Lys15)Nociceptin at the NOP receptor can be assessed through various in vitro and in vivo assays. These studies help determine whether the peptide acts as an agonist, partial agonist, or antagonist, and how it influences downstream signaling pathways.

Potential Applications[edit]

Research into (Arg14,Lys15)Nociceptin may provide insights into the development of novel analgesics or therapeutic agents targeting the NOP receptor. Understanding how modifications affect receptor interaction can lead to the design of peptides with improved therapeutic profiles.

Research and Development[edit]

Ongoing research is focused on elucidating the structure-activity relationships of nociceptin analogs, including (Arg14,Lys15)Nociceptin. Studies often involve computational modeling, receptor binding assays, and behavioral studies in animal models to assess the peptide's effects on pain perception and other physiological responses.

Also see[edit]



This peptide related article is a stub. You can help WikiMD by expanding it.


Stub icon
   This article is a  stub. You can help WikiMD by expanding it!
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.